Oral Abstract and Poster Presenters' deadline to submit their presentation materials (slides, posters) on ASCO's Speaker Center Website LATE-MAY 2025 Majority of abstracts are released onasco.org/abstractsat 5:00 PM ET (Late-breaking Abstracts will be released at 7:00 AM CT on their day o...
Oral Abstract and Poster Presenters' deadline to submit their presentation materials (slides, posters) on ASCO's Speaker Center Website LATE-MAY 2025 Majority of abstracts are released onasco.org/abstractsat 5:00 PM ET (Late-breaking Abstracts will be released at 7:00 AM CT on their day o...
the company’s innovative BRAFV600Einhibitor, in adult Langerhans cell histiocytosis (LCH) and Erdheim-Chester disease (ECD) with BRAFV600Emutation were released as a poster presentation at 2023 American Society of
47.9%, 47.0%, and 5.1% of abstracts were accepted as online publication only, poster, and oral presentation, respectively. First authors were affiliated with institutions in native English-speaking countries (NESC) in 83 (70.9%) abstracts and non-native English-speaking countries (NNESC) in 34...
Univariate and multivariate analyses were used to identify factors associated with non-compliance with guidelines.Results:We reviewed 195 PCa abstracts. Most abstracts were accepted as poster presentation (52%) followed by publication only (45%) and oral abstract (3%). The majority were clinical (...
A, et al. Patient-reported outcomes (PROs) from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (TDM1) versus trastuzumab (H) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2-pos...
A, et al. Patient-reported outcomes (PROs) from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (TDM1) versus trastuzumab (H) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer. ASCO 2019 (Abstract 513; poster presentation)....
Poster presentation at the SUO 22nd Annual Meeting; December 1-3, 2021; Miami, FL. Poster 175. 疲劳 皮疹 脂肪酶升高 淀粉酶升高 甲状腺功能减退症甲状腺功能亢进症 乏力 食欲减退 恶心 血肌酐升高 斑丘疹 ALT升高 ALT升高关节痛关节痛 Presented By Alfred Alfred Witjes at 2022 ASCO Abstract 4585 尿路...
clonoSEQ presentations of interest include: Abstract 8003 Oral Presentation 8004 Oral Presentation 7552 Poster Presentation Poster 306 8026 Poster Presentation Poster 306 7501 Oral Presentation 7502 Oral Presentation Title Date, Time, Location Phase 3 randomized study of daratumumab (DARA) + bortezomib/...
Poster Presentation Abstract #4578 FGFR3 alterations in patients who develop locally advanced or mUC, and their association with tumor subtype and clinical outcomes in patients treated with erdafitinib vs. pembrolizumab Tumor Agnostic Dise...